Suppr超能文献

相似文献

3
The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
ChemMedChem. 2010 Nov 8;5(11):1871-9. doi: 10.1002/cmdc.201000222.
4
Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.
J Biol Chem. 2015 Jan 2;290(1):529-43. doi: 10.1074/jbc.M114.608315. Epub 2014 Nov 4.
5
Non-natural peptide triazole antagonists of HIV-1 envelope gp120.
ChemMedChem. 2013 Feb;8(2):322-8. doi: 10.1002/cmdc.201200422. Epub 2012 Dec 13.
7
A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
Biochemistry. 2013 Apr 2;52(13):2245-61. doi: 10.1021/bi400166b. Epub 2013 Mar 22.
8
Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.
J Med Chem. 2015 Sep 24;58(18):7603-8. doi: 10.1021/acs.jmedchem.5b00935. Epub 2015 Sep 11.
9
HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.
Proteins. 2013 Feb;81(2):271-90. doi: 10.1002/prot.24184. Epub 2012 Oct 26.
10

引用本文的文献

2
Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability.
Curr Protein Pept Sci. 2023;24(1):59-77. doi: 10.2174/1389203723666220610120927.
3
Peptide-Based HIV Entry Inhibitors.
Adv Exp Med Biol. 2022;1366:15-26. doi: 10.1007/978-981-16-8702-0_2.
4
Peptide-Based Antiviral Drugs.
Adv Exp Med Biol. 2021;1322:261-284. doi: 10.1007/978-981-16-0267-2_10.
5
Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics.
Amino Acids. 2020 Sep;52(9):1207-1226. doi: 10.1007/s00726-020-02890-9. Epub 2020 Sep 18.
6
Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1.
ChemMedChem. 2020 May 6;15(9):799-807. doi: 10.1002/cmdc.202000038. Epub 2020 Apr 6.
8
Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.
J Pept Sci. 2019 Apr;25(4):e3155. doi: 10.1002/psc.3155. Epub 2019 Feb 27.

本文引用的文献

2
MMFF VI. MMFF94s option for energy minimization studies.
J Comput Chem. 1999 May;20(7):720-729. doi: 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X.
4
Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.
J Virol. 2007 Apr;81(7):3645-8. doi: 10.1128/JVI.01778-06. Epub 2007 Jan 24.
6
Chemokine antagonists as therapeutics: focus on HIV-1.
Annu Rev Med. 2007;58:445-59. doi: 10.1146/annurev.med.58.080105.102908.
7
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.
J Virol. 2006 Nov;80(22):11404-8. doi: 10.1128/JVI.01102-06. Epub 2006 Sep 6.
8
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
Biochemistry. 2006 Sep 12;45(36):10973-80. doi: 10.1021/bi061193r.
10
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.
J Biol Chem. 2006 Jul 7;281(27):18787-92. doi: 10.1074/jbc.M602422200. Epub 2006 Apr 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验